Author

A. L. Gintsburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:bacteria (other)· 1 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. E. Sinyavin· 2 shared A. N. Zolotar· 2 shared D. A. Egorova· 2 shared D. A. Kleymenov· 2 shared D. V. Shcheblyakov· 2 shared D. V. Voronina· 2 shared D. Y. Logunov· 2 shared E. N. Bykonia· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. E. Sinyavin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Major role of S-glycoprotein in providing immunogenicity and protective immunity in mRNA lipid nanoparticle vaccines based on SARS-CoV-2 structural proteins

E. N. Bykonia, D. A. Kleymenov, V. A. Gushchin, A. E. Sinyavin, E. P. Mazunina, N. Kuznetsova, S. R. Kozlova, A. N. Zolotar, E. V. Shidlovskaya, E. V. Usachev, A. A. Pochtovyi, D. D. Kustova, I. A. Ivanov, S. E. Dmitriev, R. A. Ivanov, , A. L. Gintsburg

This study evaluates mRNA-LNP vaccines encoding SARS-CoV-2 structural proteins, finding that the S protein enhances immune responses to N protein, while M protein has low immunogenicity.

bioRxiv · Dec 30, 2023Immunology

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

E. P. Mazunina, V. A. Gushchin, D. A. Kleymenov, A. E. Sinyavin, E. I. Burtseva, M. M. Shmarov, E. A. Mukasheva, E. N. Bykonia, S. R. Kozlova, E. A. Evgrafova, A. N. Zolotar, E. V. Shidlovskaya, E. S. Kirillova, A. S. Krepkaia, E. V. Usachev, , A. L. Gintsburg

This study develops a trivalent mRNA vaccine candidate for seasonal flu, showing higher immunogenicity and cross-specific humoral immune response compared to an inactivated split vaccine.

bioRxiv · Dec 30, 2023Immunology

Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection

D. V. Voronina, A. S. Bandelyuk, A. S. Dzharullaeva, O. Popova, V. Y. Kan, I. B. Esmagambetov, I. A. Favorskaya, D. V. Shcheblyakov, B. S. Naroditskiy, A. L. Gintsburg

This study modifies two single-domain antibodies to enhance their neutralizing activity against multiple influenza A virus subtypes and demonstrates their protective efficacy in mice.

bioRxiv · Sep 29, 2022 · PreprintImmunology

Biofilm matrix proteome of clinical strain of P. aeruginosa

D. A. Egorova, A. I. Solovyev, N. B. Polyakov, K. V. Danilova, A. A. Scherbakova, I. N. Kravtsov, M. A. Dmitrieva, V. S. Rykova, I. L. Tutykhina, Y. M. Romanova, A. L. Gintsburg

The paper reports the first biofilm matrix proteome of a clinical P. aeruginosa isolate, identifies enriched bioprocess groups, and discusses implications for antibiofilm therapeutics.

bioRxiv · Dec 21, 2021 · PreprintMicrobiology

Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant

I. A. Favorskaya, D. V. Shcheblyakov, I. B. Esmagambetov, I. V. Dolzhikova, I. A. Alekseeva, A. I. Korobkova, D. V. Voronina, E. I. Ryabova, A. A. Derkaev, A. V. Kovyrshina, A. A. Iliukhina, A. G. Botikov, O. L. Voronina, D. A. Egorova, O. V. Zubkova, , A. L. Gintsburg

The paper identifies single-domain antibodies that neutralize SARS-CoV-2 variants, including Omicron, with enhanced potency through dimeric modifications.

bioRxiv · Nov 24, 2021 · PreprintImmunology